Fig. 1From: Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinomaIC50-values for a Alisertib, b Saracatinib, c MK1775, d Temsirolimus and e MK2206. IC50-values were determined by colony-forming assays. IGROV1 and SKOV3ip cells were incubated for 48 h with accordant PKI concentrations ranging from 0.1–1000 nMBack to article page